SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

doi:10.1007/s12094-015-1455-z

. 2015 Dec;17(12):1020-9.

doi: 10.1007/s12094-015-1455-z. Epub 2015 Dec 21.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

R García-Campelo¹, R Bernabé², M Cobo³, J Corral⁴, J Coves⁵, M Dómine⁶, E Nadal⁷, D Rodriguez-Abreu⁸, N Viñolas⁹, B Massuti¹⁰

Affiliations

¹ Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Coruña, Spain. maria.rosario.garcia.campelo@sergas.es.
² Medical Oncology Department, Hospital Universitario Nstra. Sra. de Valme, Seville, Spain.
³ Medical Oncology Department, Hospital Universitario Málaga, Málaga, Spain.
⁴ Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain.
⁵ Medical Oncology Department, Hospital Son Llatzer, Palma De Mallorca, Spain.
⁶ Hospital Universitario Fundación Jiménez Díaz. Oncohealth Institute, Madrid, Spain.
⁷ Medical Oncology Department, Instituto Catalán de Oncología, L'Hospitalet, Barcelona, Spain.
⁸ Medical Oncology Department, Hospital Universitario Insular de Las Palmas de Gran Canaria, Las Palmas, Spain.
⁹ Medical Oncology Department, Hospital Clinic I Provincial de Barcelona, Barcelona, Spain.
¹⁰ Medical Oncology Department, Hospital General Universitario Alicante, Alicante, Spain.

PMID: 26691657
PMCID: PMC4689744
DOI: 10.1007/s12094-015-1455-z

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

R García-Campelo et al. Clin Transl Oncol. 2015 Dec.

. 2015 Dec;17(12):1020-9.

doi: 10.1007/s12094-015-1455-z. Epub 2015 Dec 21.

Authors

R García-Campelo¹, R Bernabé², M Cobo³, J Corral⁴, J Coves⁵, M Dómine⁶, E Nadal⁷, D Rodriguez-Abreu⁸, N Viñolas⁹, B Massuti¹⁰

Affiliations

¹ Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Coruña, Spain. maria.rosario.garcia.campelo@sergas.es.
² Medical Oncology Department, Hospital Universitario Nstra. Sra. de Valme, Seville, Spain.
³ Medical Oncology Department, Hospital Universitario Málaga, Málaga, Spain.
⁴ Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain.
⁵ Medical Oncology Department, Hospital Son Llatzer, Palma De Mallorca, Spain.
⁶ Hospital Universitario Fundación Jiménez Díaz. Oncohealth Institute, Madrid, Spain.
⁷ Medical Oncology Department, Instituto Catalán de Oncología, L'Hospitalet, Barcelona, Spain.
⁸ Medical Oncology Department, Hospital Universitario Insular de Las Palmas de Gran Canaria, Las Palmas, Spain.
⁹ Medical Oncology Department, Hospital Clinic I Provincial de Barcelona, Barcelona, Spain.
¹⁰ Medical Oncology Department, Hospital General Universitario Alicante, Alicante, Spain.

PMID: 26691657
PMCID: PMC4689744
DOI: 10.1007/s12094-015-1455-z

Abstract

Lung cancer is the most common cancer worldwide as well as the leading cause of cancer related deaths as reported by Torre et al (CA Cancer J Clin 65:87-108, 2015]. Non-small cell lung cancer (NSCLC) accounts for up to 85 % of all lung cancers. Multiple advances in the staging, diagnostic procedures, therapeutic options, as well as molecular knowledge have been achieved during the past years, although the overall outlook has not greatly changed for the majority of patients with the overall 5-year survival having marginally increased over the last decade from 15.7 to 17.4 % as reported by Howlader et al. (SEER Cancer Statistics Review 2015).

Keywords: Chemotherapy; NSCLC; Radiotherapy; Targeted therapies.

PubMed Disclaimer

Figures

**Fig. 1**
Treatment algorithm for Stage III

**Fig. 2**
Treatment algorithm for Stage IV

See this image and copyright information in PMC

Cited by

Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
Zhao Y, Wang H, Shi Y, Cai S, Wu T, Yan G, Cheng S, Cui K, Xi Y, Qi X, Zhang J, Ma W. Zhao Y, et al. Oncotarget. 2017 Jan 24;8(4):7014-7024. doi: 10.18632/oncotarget.12294. Oncotarget. 2017. PMID: 27690345 Free PMC article.
Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Couñago F, Rodríguez A, Calvo P, Luna J, Monroy JL, Taboada B, Díaz V, Rodríguez de Dios N. Couñago F, et al. Clin Transl Oncol. 2017 Jan;19(1):31-43. doi: 10.1007/s12094-016-1512-2. Epub 2016 Apr 22. Clin Transl Oncol. 2017. PMID: 27106020 Review.
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.
González-Larriba JL, Lázaro-Quintela M, Cobo M, Dómine M, Majem M, García-Campelo R. González-Larriba JL, et al. Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S21-S34. doi: 10.21037/tlcr.2017.10.03. Transl Lung Cancer Res. 2017. PMID: 29299405 Free PMC article. Review.
Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
Deneka AY, Haber L, Kopp MC, Gaponova AV, Nikonova AS, Golemis EA. Deneka AY, et al. PLoS One. 2017 Apr 28;12(4):e0176747. doi: 10.1371/journal.pone.0176747. eCollection 2017. PLoS One. 2017. PMID: 28453558 Free PMC article.
Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum.
Wen-Xiu X, Xiao-Wei Z, Hai-Ying D, Ying-Hui T, Si-Si K, Xiao-Fang Z, Huang P. Wen-Xiu X, et al. Medicine (Baltimore). 2018 Dec;97(51):e13652. doi: 10.1097/MD.0000000000013652. Medicine (Baltimore). 2018. PMID: 30572481 Free PMC article.

See all "Cited by" articles

References

1. Torre LA, Bray F, Siegel RL. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262. - DOI - PubMed
1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2012. Bethesda: National Cancer Institute; 2015.
1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–859. doi: 10.1097/JTO.0b013e318290868f. - DOI - PMC - PubMed
1. Felip E, Concha A, de Castro J, Gómez-Román J, Garrido P, Ramírez J, et al. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015;17(2):103–112. doi: 10.1007/s12094-014-1248-9. - DOI - PubMed
1. Rami-porta R, Crowley JJ, Goldstraw P. The revised TNM system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15(1):4–9. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Torre LA, Bray F, Siegel RL. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262. - DOI - PubMed

[2] Torre LA, Bray F, Siegel RL. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262. - DOI - PubMed

[3] Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2012. Bethesda: National Cancer Institute; 2015.

[4] Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2012. Bethesda: National Cancer Institute; 2015.

[5] Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–859. doi: 10.1097/JTO.0b013e318290868f. - DOI - PMC - PubMed

[6] Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–859. doi: 10.1097/JTO.0b013e318290868f. - DOI - PMC - PubMed

[7] Felip E, Concha A, de Castro J, Gómez-Román J, Garrido P, Ramírez J, et al. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015;17(2):103–112. doi: 10.1007/s12094-014-1248-9. - DOI - PubMed

[8] Felip E, Concha A, de Castro J, Gómez-Román J, Garrido P, Ramírez J, et al. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015;17(2):103–112. doi: 10.1007/s12094-014-1248-9. - DOI - PubMed

[9] Rami-porta R, Crowley JJ, Goldstraw P. The revised TNM system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15(1):4–9. - PubMed

[10] Rami-porta R, Crowley JJ, Goldstraw P. The revised TNM system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15(1):4–9. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

Affiliations

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous